Intensity Therapeutics Files to Resume Enrollment in Breast Cancer Study After Positive Data

Key Facts

Intensity Therapeutics (INTS) has filed to resume patient enrollment in its Phase 2 INVINCIBLE-4 study for triple-negative breast cancer, following a previous pause in the trial. This move follows promising preliminary data showing that 71.4% of patients treated with INT230-6 achieved a pathological complete response (pCR), significantly outperforming the 33% rate in the standard care group. The study also demonstrated a superior safety profile, with a 44% reduction in severe adverse events. Resuming enrollment marks a critical step for the company as it advances its clinical development path and seeks to disrupt current oncology treatment standards. Market sentiment remains bullish as the company moves to capitalize on these strong efficacy and safety signals while resolving the trial's temporary pause.